JP2006502117A5 - - Google Patents

Info

Publication number

JP2006502117A5

JP2006502117A5 JP2004521887A JP2004521887A JP2006502117A5 JP 2006502117 A5 JP2006502117 A5 JP 2006502117A5 JP 2004521887 A JP2004521887 A JP 2004521887A JP 2004521887 A JP2004521887 A JP 2004521887A JP 2006502117 A5 JP2006502117 A5 JP 2006502117A5

Authority

JP

Japan

Prior art keywords

composition

effective amount

oxyalkylene

group

administered

Prior art date

2003-07-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000005702 oxyalkylene group Chemical group 0.000 claims 10
• 150000001875 compounds Chemical class 0.000 claims 9
• 239000003795 chemical substances by application Substances 0.000 claims 6
• 230000006698 induction Effects 0.000 claims 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
• 239000003276 histone deacetylase inhibitor Substances 0.000 claims 5
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
• 125000000217 alkyl group Chemical group 0.000 claims 4
• 229960003668 docetaxel Drugs 0.000 claims 4
• 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 4
• 239000012624 DNA alkylating agent Substances 0.000 claims 3
• 241000124008 Mammalia Species 0.000 claims 3
• 229930012538 Paclitaxel Natural products 0.000 claims 3
• 102000004243 Tubulin Human genes 0.000 claims 3
• 108090000704 Tubulin Proteins 0.000 claims 3
• 239000002246 antineoplastic agent Substances 0.000 claims 3
• 125000003118 aryl group Chemical group 0.000 claims 3
• 229960004562 carboplatin Drugs 0.000 claims 3
• 190000008236 carboplatin Chemical compound 0.000 claims 3
• 230000000973 chemotherapeutic effect Effects 0.000 claims 3
• 229940127089 cytotoxic agent Drugs 0.000 claims 3
• 229960001592 paclitaxel Drugs 0.000 claims 3
• 229910052697 platinum Inorganic materials 0.000 claims 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical group CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
• 229940126161 DNA alkylating agent Drugs 0.000 claims 2
• 102000003964 Histone deacetylase Human genes 0.000 claims 2
• 108090000353 Histone deacetylase Proteins 0.000 claims 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
• 125000003545 alkoxy group Chemical group 0.000 claims 2
• 230000000259 anti-tumor effect Effects 0.000 claims 2
• 125000003710 aryl alkyl group Chemical group 0.000 claims 2
• 125000004104 aryloxy group Chemical group 0.000 claims 2
• 229960004316 cisplatin Drugs 0.000 claims 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
• 229960003901 dacarbazine Drugs 0.000 claims 2
• 125000002541 furyl group Chemical group 0.000 claims 2
• 125000001624 naphthyl group Chemical group 0.000 claims 2
• 239000002777 nucleoside Substances 0.000 claims 2
• 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
• 229960001756 oxaliplatin Drugs 0.000 claims 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
• 229960004964 temozolomide Drugs 0.000 claims 2
• 125000001544 thienyl group Chemical group 0.000 claims 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
• 125000004103 aminoalkyl group Chemical group 0.000 claims 1
• GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 1
• 125000004432 carbon atom Chemical group C* 0.000 claims 1
• 229960004397 cyclophosphamide Drugs 0.000 claims 1
• 229960000390 fludarabine Drugs 0.000 claims 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 150000002367 halogens Chemical class 0.000 claims 1
• 229910052739 hydrogen Inorganic materials 0.000 claims 1
• 239000001257 hydrogen Substances 0.000 claims 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 230000002452 interceptive effect Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000000178 monomer Substances 0.000 claims 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
• 125000002456 taxol group Chemical group 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1